about
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.Anti-HER2 vaccines: new prospects for breast cancer therapyBevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxelMetastasis: recent discoveries and novel treatment strategies.Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cellsRisk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.VEGF inhibitors and prostate cancer therapyState of the art in anti-cancer mAbs.Bevacizumab in endometrial cancer treatment.Bevacizumab for the treatment of cervical cancer.Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.Targeted endometrial cancer therapy as a future prospect.Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.Current opinion on bevacizumab on endometrial cancer treatment.Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports
P2860
Q33378865-E75F49E4-65FE-4893-9680-831E938E5001Q34105959-9E69C7AA-A097-44D4-B264-4FA7FAFC5CF6Q35433194-89D9F3D3-BC14-4428-AE47-F240DA50C9CBQ36407511-C9DFB319-362D-4C22-B8EC-FF3C2F7CC6C1Q36742070-FA637944-0E78-4FCA-A3CF-9181A5753C58Q37062140-9C5E87CC-F3AE-4977-82AE-DF004C53937FQ37174938-6312C248-46B1-487F-8159-5685B5E56E2BQ37264085-600E0E73-7C51-4A36-A2E4-777EEC06EE70Q37655585-98B49FA2-581E-4CF1-BBEE-B4250A2FA67CQ37994752-2570B619-0336-4706-9F03-8F5F53376AB5Q38706483-F1374869-E561-4A8C-9E35-E77E7226BF45Q38969949-97C13BC4-8418-4FAB-A01D-427526425F8BQ39454208-E2ECEF82-79AE-4494-9CD3-2808ABDE622EQ39996613-0D2D33FF-252A-461A-9745-C655880C43C9Q49539698-4BA66FB8-5D3C-461C-9632-13525B284BA2Q50034069-A1A728EB-D826-4FDA-BFE6-2F559B23E529Q53225923-93AF07C4-49B3-4901-9C58-2CE41103BF31Q57788551-0C046B3A-5407-4BCB-A815-501BD8A71184
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bevacizumab in the management of solid tumors.
@en
type
label
Bevacizumab in the management of solid tumors.
@en
prefLabel
Bevacizumab in the management of solid tumors.
@en
P2860
P356
P1476
Bevacizumab in the management of solid tumors.
@en
P2093
Agustin A Garcia
Roy L Pañares
P2860
P304
P356
10.1586/14737140.7.4.433
P577
2007-04-01T00:00:00Z